Vivesto（OMA）株式概要Vivesto ABは、スウェーデンにおいてヒトおよび獣医の腫瘍学分野における医薬品の開発、製造、販売、マーケティングを行っている。 詳細OMA ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬過去5年間の収益は年間36.4%増加しました。 リスク分析過去1年間で株主の希薄化は大幅に進んだ キャッシュランウェイが1年未満である German市場と比較して、過去 3 か月間の株価の変動が非常に大きい今後3年間の収益は年平均27.1%減少すると予測されている。 +3 さらなるリスクすべてのリスクチェックを見るOMA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,068 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,068 investors already sharing narrativesYour Fair Value€Current Price€0.75該当なし内在価値ディスカウントEst. Revenue$PastFuture-376m139m2016201920222025202620282031Revenue SEK 15.2Earnings SEK 2.7AdvancedSet Fair ValueView all narrativesVivesto AB 競合他社2investSymbol: DB:2INVMarket cap: €45.1mNovogeniaSymbol: MUN:7V0Market cap: €78.0mRespiratoriusSymbol: DB:HF00Market cap: €22.9mBiomark DiagnosticsSymbol: DB:20BMarket cap: €33.4m価格と性能株価の高値、安値、推移の概要Vivesto過去の株価現在の株価SEK 0.7552週高値SEK 1.9152週安値SEK 0.14ベータ0.921ヶ月の変化-2.36%3ヶ月変化210.83%1年変化-51.87%3年間の変化n/a5年間の変化n/aIPOからの変化-99.62%最新ニュースNew Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.70m market cap, or US$9.90m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).New Risk • Jun 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr41m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.58m market cap, or US$9.77m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr41m). Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.61m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (65% average daily change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.61m market cap, or US$9.79m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr63m net loss in 3 years).お知らせ • Jun 17Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology StudyVivesto AB reported positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The study is the first conducted with Cantrixil administrated intravenously (i.v.) in a larger animal species (dog). The data support continued development of Cantrixil toward a Phase I clinical trial in acute myeloid leukemia (AML) in humans, and a pilot study in dogs with cancer. The study results demonstrate that i.v. Cantrixil was well tolerated at all dose levels, with no adverse findings, no cardiovascular effects, and no signs of local irritation or toxicity at the injection site. Pharmacokinetic parameters, including blood concentration levels and half-life, were consistent with expectations and complement prior preclinical data. In the PK/toxicology study, four dogs received increasing i.v. doses of Cantrixil in three rounds at 2, 5 and 10 mg/kg. The study design and day 7 assessments support the intended once-weekly dosing frequency for both humans and dogs. Cantrixil was well tolerated by all dogs, with no adverse or toxicologically relevant findings. No cardiovascular adverse effects were reported, a particularly important finding as cardiovascular toxicity is a known and often dose-limiting risk for cytotoxic agents. Furthermore, there were no local signs of irritation or toxicity at the injection site. Hematological and clinical biochemistry parameters, which were analyzed before treatment start and 7 days after each treatment administration, a common timepoint for assessing cytotoxic agents, showed no alterations. The pharmacokinetic parameters of Cantrixil, including blood concentration levels, were in line with previous observations from the in vivo study performed in a mouse model of AML earlier last year. Drug half-life was as expected, confirming that the i.v. formulation performs as intended and is consistent with existing preclinical documentation. Together with previous findings, these new results support the continued advancement of Cantrixil toward a Phase I clinical trial in AML in humans, in parallel with continued CMC development to produce clinical trial material. As previously announced, Vivesto is also developing Cantrixil for dogs with cancer, building on its anti-cancer mechanism of action and synergies with the company’s existing veterinary oncology program.Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Pal Ryfors was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering最新情報をもっと見るRecent updatesNew Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.70m market cap, or US$9.90m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).New Risk • Jun 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr41m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.58m market cap, or US$9.77m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr41m). Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.61m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (65% average daily change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.61m market cap, or US$9.79m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr63m net loss in 3 years).お知らせ • Jun 17Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology StudyVivesto AB reported positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The study is the first conducted with Cantrixil administrated intravenously (i.v.) in a larger animal species (dog). The data support continued development of Cantrixil toward a Phase I clinical trial in acute myeloid leukemia (AML) in humans, and a pilot study in dogs with cancer. The study results demonstrate that i.v. Cantrixil was well tolerated at all dose levels, with no adverse findings, no cardiovascular effects, and no signs of local irritation or toxicity at the injection site. Pharmacokinetic parameters, including blood concentration levels and half-life, were consistent with expectations and complement prior preclinical data. In the PK/toxicology study, four dogs received increasing i.v. doses of Cantrixil in three rounds at 2, 5 and 10 mg/kg. The study design and day 7 assessments support the intended once-weekly dosing frequency for both humans and dogs. Cantrixil was well tolerated by all dogs, with no adverse or toxicologically relevant findings. No cardiovascular adverse effects were reported, a particularly important finding as cardiovascular toxicity is a known and often dose-limiting risk for cytotoxic agents. Furthermore, there were no local signs of irritation or toxicity at the injection site. Hematological and clinical biochemistry parameters, which were analyzed before treatment start and 7 days after each treatment administration, a common timepoint for assessing cytotoxic agents, showed no alterations. The pharmacokinetic parameters of Cantrixil, including blood concentration levels, were in line with previous observations from the in vivo study performed in a mouse model of AML earlier last year. Drug half-life was as expected, confirming that the i.v. formulation performs as intended and is consistent with existing preclinical documentation. Together with previous findings, these new results support the continued advancement of Cantrixil toward a Phase I clinical trial in AML in humans, in parallel with continued CMC development to produce clinical trial material. As previously announced, Vivesto is also developing Cantrixil for dogs with cancer, building on its anti-cancer mechanism of action and synergies with the company’s existing veterinary oncology program.Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Pal Ryfors was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offeringお知らせ • Nov 20Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offeringお知らせ • Nov 08Vivesto AB, Annual General Meeting, May 07, 2026Vivesto AB, Annual General Meeting, May 07, 2026. Location: stockholm Swedenお知らせ • Apr 08Vivesto AB, Annual General Meeting, May 08, 2025Vivesto AB, Annual General Meeting, May 08, 2025, at 09:00 W. Europe Standard Time. Location: at gustav iii:s boulevard 42, ground floor, se-169 73 solna, Swedenお知らせ • Apr 01Vivesto AB Reports Positive Cantrixil Results in an Animal Hematological Cancer ModelVivesto AB announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data. The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe. With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.お知らせ • Jan 16Vivesto AB Receives Approval to Initiate A Dose-Finding Study of Paccal Vet in CatsVivesto AB announced that ethical approval has been obtained from the US Veterinary Review Board Clinical Studies Committee for a planned Paccal Vet dose-finding clinical trial in cats with cancer. The approval authorizes the participating clinical sites to enroll patients in the study. The dose-finding study will initially be conducted at two clinical sites in Washington and Oregon, with the possibility to include more sites as the study progresses. The study will be managed by CASTR Alliance, the contract research organization (CRO) currently running Paccal Vet's pilot clinical trial in dogs with splenic hemangiosarcoma in the US. FDA's Center for Veterinary Medicine, CVM, has previously confirmed that the cat study can be conducted under the existing INAD (Investigational New Animal Drug). The dose-finding study will follow the 3+3 design, a widely used approach to determine the maximum tolerated dose (MTD). A maximum of 12 cats will be included, receiving Paccal Vet treatment in groups of three, with doses escalating for each group until the MTD is identified. This study design ensures patient safety while effectively identifying the appropriate dosage for Paccal Vet administration in cats.お知らせ • Dec 20Vivesto Strengthens Cantrixil Program with New Preclinical Results and Patent ApplicationVivesto AB, announced that positive results were obtained from preclinical studies with combination treatments within the company’s Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position. The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025. Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.お知らせ • Jan 30Vivesto's International Patent Application for XR-18 Receives Positive DecisionVivesto AB, announced that the European Patent Office (EPO) has granted a positive approval regarding the patentability of the company's XR-18 technology platform in Vivesto's international patent application (Patent Cooperation Treaty; PCT). The patent application for XR-18 is now in an international phase, which provides the opportunity to apply for patents in countries that are part of the PCT collaboration (157 countries). Vivesto now has two independent assessments that have been positive about the patentability of the XR-18 invention; EPO and earlier from the Swedish Intellectual Property Office (PRV). The company will now evaluate in which countries the company intends to seek protection.お知らせ • Dec 28Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient RecruitmentVivesto AB announced that the US Veterinary Review Board Clinical Studies Committee approved the company's planned Paccal Vet open label, pilot clinical study in dogs with splenic hemangiosarcoma following splenectomy. Clinical sites have been chosen and will be ready to start activities after supply of Paccal Vet (investigational veterinary product, IVP) in January. A planned interim analysis is expected in the second half of 2024. The Paccal Vet development program was discussed with FDA earlier this year. No further Agency approval is required prior to study start. The study is an open label, exploratory indication finding study in dogs with different stages of splenic hemangiosarcoma (HSA) following splenectomy. The study will include 4 treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate 2 cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at 6 clinical sites in Washington and Oregon. First patients are expected to be dosed in early 2024 and a planned interim analysis is expected in the second half of 2024. If promising activity in either cohort is shown, the study shall be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.お知らせ • Nov 24Vivesto AB (publ) Announces Composition of Nomination CommitteeIn accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023. The Nomination Committee for the 2024 Annual General Meeting comprises the following members: Per Arwidsson, appointed by Arwidsro, Håkan Lagerberg, appointed by Mastan AB, and Peter Zonabend, Chairman of the Board of Vivesto. Per Arwidsson has been appointed Chairman of the Nomination Committee.お知らせ • Nov 18Vivesto AB, Annual General Meeting, May 23, 2024Vivesto AB, Annual General Meeting, May 23, 2024.お知らせ • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024New Risk • Oct 12New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr3.0m revenue, or US$277k). Minor Risk Market cap is less than US$100m (€9.95m market cap, or US$10.5m).株主還元OMADE BiotechsDE 市場7D4.5%-1.1%-0.7%1Y-51.9%11.6%-0.9%株主還元を見る業界別リターン: OMA過去 1 年間で11.6 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: OMAは、過去 1 年間で-0.9 % のリターンを上げたGerman市場を下回りました。価格変動Is OMA's price volatile compared to industry and market?OMA volatilityOMA Average Weekly Movement144.3%Biotechs Industry Average Movement7.7%Market Average Movement5.4%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.7%安定した株価: OMAの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: OMAの 週次ボラティリティ は、過去 1 年間で94%から144%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト19884Erik Kinnmanwww.vivesto.comVivesto ABは、スウェーデンにおいて、ヒトおよび獣医の腫瘍学分野における医薬品の開発、製造、マーケティング、販売を行っている。主力製品は卵巣がん治療薬のアペレア（パクリタキセルミセル）。同社の製品ポートフォリオには、細胞毒素であるドセタキセルとXR-17を組み合わせた特許製剤であるドセタキセルミセル（前立腺がん治療薬として第1b相臨床試験中）、卵巣がん治療薬Cantrixilなどがある。動物用製品ポートフォリオには、XR-17カプセル化技術を用いたパクリタキセル製剤であるPaccal Vet（犬肥満細胞腫治療薬）、特許製剤であるドキソルビシン製剤であるDoxophos Vet（リンパ腫治療薬）などがある。同社は以前はOasmia Pharmaceutical AB（publ）として知られていたが、2022年3月にVivesto ABに社名を変更した。ビベストABは1988年に設立され、スウェーデンのソルナに本社を置いている。もっと見るVivesto AB 基礎のまとめVivesto の収益と売上を時価総額と比較するとどうか。OMA 基礎統計学時価総額€8.36m収益（TTM）-€2.96m売上高(TTM)n/a0.0xP/Sレシオ-2.8xPER（株価収益率OMA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OMA 損益計算書（TTM）収益SEK 0売上原価SEK 0売上総利益SEK 0その他の費用SEK 32.69m収益-SEK 32.69m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.95グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%OMA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/20 04:26終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vivesto AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Camilla OxhamreCarnegie Investment Bank ABKlas PalinDNB Carnegie Commissioned ResearchSusie JanaEdison Investment Research2 その他のアナリストを表示
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.70m market cap, or US$9.90m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).
New Risk • Jun 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr41m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.58m market cap, or US$9.77m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr41m). Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).
New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.61m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (65% average daily change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.61m market cap, or US$9.79m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr63m net loss in 3 years).
お知らせ • Jun 17Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology StudyVivesto AB reported positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The study is the first conducted with Cantrixil administrated intravenously (i.v.) in a larger animal species (dog). The data support continued development of Cantrixil toward a Phase I clinical trial in acute myeloid leukemia (AML) in humans, and a pilot study in dogs with cancer. The study results demonstrate that i.v. Cantrixil was well tolerated at all dose levels, with no adverse findings, no cardiovascular effects, and no signs of local irritation or toxicity at the injection site. Pharmacokinetic parameters, including blood concentration levels and half-life, were consistent with expectations and complement prior preclinical data. In the PK/toxicology study, four dogs received increasing i.v. doses of Cantrixil in three rounds at 2, 5 and 10 mg/kg. The study design and day 7 assessments support the intended once-weekly dosing frequency for both humans and dogs. Cantrixil was well tolerated by all dogs, with no adverse or toxicologically relevant findings. No cardiovascular adverse effects were reported, a particularly important finding as cardiovascular toxicity is a known and often dose-limiting risk for cytotoxic agents. Furthermore, there were no local signs of irritation or toxicity at the injection site. Hematological and clinical biochemistry parameters, which were analyzed before treatment start and 7 days after each treatment administration, a common timepoint for assessing cytotoxic agents, showed no alterations. The pharmacokinetic parameters of Cantrixil, including blood concentration levels, were in line with previous observations from the in vivo study performed in a mouse model of AML earlier last year. Drug half-life was as expected, confirming that the i.v. formulation performs as intended and is consistent with existing preclinical documentation. Together with previous findings, these new results support the continued advancement of Cantrixil toward a Phase I clinical trial in AML in humans, in parallel with continued CMC development to produce clinical trial material. As previously announced, Vivesto is also developing Cantrixil for dogs with cancer, building on its anti-cancer mechanism of action and synergies with the company’s existing veterinary oncology program.
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Pal Ryfors was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.70m market cap, or US$9.90m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).
New Risk • Jun 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr41m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average daily change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.58m market cap, or US$9.77m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr41m). Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).
New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.61m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (65% average daily change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€8.61m market cap, or US$9.79m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr63m net loss in 3 years).
お知らせ • Jun 17Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology StudyVivesto AB reported positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The study is the first conducted with Cantrixil administrated intravenously (i.v.) in a larger animal species (dog). The data support continued development of Cantrixil toward a Phase I clinical trial in acute myeloid leukemia (AML) in humans, and a pilot study in dogs with cancer. The study results demonstrate that i.v. Cantrixil was well tolerated at all dose levels, with no adverse findings, no cardiovascular effects, and no signs of local irritation or toxicity at the injection site. Pharmacokinetic parameters, including blood concentration levels and half-life, were consistent with expectations and complement prior preclinical data. In the PK/toxicology study, four dogs received increasing i.v. doses of Cantrixil in three rounds at 2, 5 and 10 mg/kg. The study design and day 7 assessments support the intended once-weekly dosing frequency for both humans and dogs. Cantrixil was well tolerated by all dogs, with no adverse or toxicologically relevant findings. No cardiovascular adverse effects were reported, a particularly important finding as cardiovascular toxicity is a known and often dose-limiting risk for cytotoxic agents. Furthermore, there were no local signs of irritation or toxicity at the injection site. Hematological and clinical biochemistry parameters, which were analyzed before treatment start and 7 days after each treatment administration, a common timepoint for assessing cytotoxic agents, showed no alterations. The pharmacokinetic parameters of Cantrixil, including blood concentration levels, were in line with previous observations from the in vivo study performed in a mouse model of AML earlier last year. Drug half-life was as expected, confirming that the i.v. formulation performs as intended and is consistent with existing preclinical documentation. Together with previous findings, these new results support the continued advancement of Cantrixil toward a Phase I clinical trial in AML in humans, in parallel with continued CMC development to produce clinical trial material. As previously announced, Vivesto is also developing Cantrixil for dogs with cancer, building on its anti-cancer mechanism of action and synergies with the company’s existing veterinary oncology program.
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Pal Ryfors was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
お知らせ • Nov 20Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
お知らせ • Nov 08Vivesto AB, Annual General Meeting, May 07, 2026Vivesto AB, Annual General Meeting, May 07, 2026. Location: stockholm Sweden
お知らせ • Apr 08Vivesto AB, Annual General Meeting, May 08, 2025Vivesto AB, Annual General Meeting, May 08, 2025, at 09:00 W. Europe Standard Time. Location: at gustav iii:s boulevard 42, ground floor, se-169 73 solna, Sweden
お知らせ • Apr 01Vivesto AB Reports Positive Cantrixil Results in an Animal Hematological Cancer ModelVivesto AB announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data. The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe. With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.
お知らせ • Jan 16Vivesto AB Receives Approval to Initiate A Dose-Finding Study of Paccal Vet in CatsVivesto AB announced that ethical approval has been obtained from the US Veterinary Review Board Clinical Studies Committee for a planned Paccal Vet dose-finding clinical trial in cats with cancer. The approval authorizes the participating clinical sites to enroll patients in the study. The dose-finding study will initially be conducted at two clinical sites in Washington and Oregon, with the possibility to include more sites as the study progresses. The study will be managed by CASTR Alliance, the contract research organization (CRO) currently running Paccal Vet's pilot clinical trial in dogs with splenic hemangiosarcoma in the US. FDA's Center for Veterinary Medicine, CVM, has previously confirmed that the cat study can be conducted under the existing INAD (Investigational New Animal Drug). The dose-finding study will follow the 3+3 design, a widely used approach to determine the maximum tolerated dose (MTD). A maximum of 12 cats will be included, receiving Paccal Vet treatment in groups of three, with doses escalating for each group until the MTD is identified. This study design ensures patient safety while effectively identifying the appropriate dosage for Paccal Vet administration in cats.
お知らせ • Dec 20Vivesto Strengthens Cantrixil Program with New Preclinical Results and Patent ApplicationVivesto AB, announced that positive results were obtained from preclinical studies with combination treatments within the company’s Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position. The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025. Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.
お知らせ • Jan 30Vivesto's International Patent Application for XR-18 Receives Positive DecisionVivesto AB, announced that the European Patent Office (EPO) has granted a positive approval regarding the patentability of the company's XR-18 technology platform in Vivesto's international patent application (Patent Cooperation Treaty; PCT). The patent application for XR-18 is now in an international phase, which provides the opportunity to apply for patents in countries that are part of the PCT collaboration (157 countries). Vivesto now has two independent assessments that have been positive about the patentability of the XR-18 invention; EPO and earlier from the Swedish Intellectual Property Office (PRV). The company will now evaluate in which countries the company intends to seek protection.
お知らせ • Dec 28Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient RecruitmentVivesto AB announced that the US Veterinary Review Board Clinical Studies Committee approved the company's planned Paccal Vet open label, pilot clinical study in dogs with splenic hemangiosarcoma following splenectomy. Clinical sites have been chosen and will be ready to start activities after supply of Paccal Vet (investigational veterinary product, IVP) in January. A planned interim analysis is expected in the second half of 2024. The Paccal Vet development program was discussed with FDA earlier this year. No further Agency approval is required prior to study start. The study is an open label, exploratory indication finding study in dogs with different stages of splenic hemangiosarcoma (HSA) following splenectomy. The study will include 4 treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate 2 cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at 6 clinical sites in Washington and Oregon. First patients are expected to be dosed in early 2024 and a planned interim analysis is expected in the second half of 2024. If promising activity in either cohort is shown, the study shall be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.
お知らせ • Nov 24Vivesto AB (publ) Announces Composition of Nomination CommitteeIn accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023. The Nomination Committee for the 2024 Annual General Meeting comprises the following members: Per Arwidsson, appointed by Arwidsro, Håkan Lagerberg, appointed by Mastan AB, and Peter Zonabend, Chairman of the Board of Vivesto. Per Arwidsson has been appointed Chairman of the Nomination Committee.
お知らせ • Nov 18Vivesto AB, Annual General Meeting, May 23, 2024Vivesto AB, Annual General Meeting, May 23, 2024.
お知らせ • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024
New Risk • Oct 12New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr3.0m revenue, or US$277k). Minor Risk Market cap is less than US$100m (€9.95m market cap, or US$10.5m).
